Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide DS versus ciclopirox olamine 1% cream in seborrheic dermatitis
2020-000720-19Phase 4Completed
- Sponsor
- IDI Farmaceutici
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nicotinamide in seborrheic dermatitis (SD) (2 arms), sponsored by IDI Farmaceutici. Primary endpoint: Percentage of subjects with improved SASI index. Started May 2021; status: completed.
02
Drugs
nicotinamide
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on 2020-000720-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000720-19.